C-REACTIVE PROTEIN IN NON ALCOHOLIC FATTY LIVER DISEASE (NAFLD)

Rajni  Dawar; Tabassum  Yasmin

doi:10.22270/ijmspr.v1i3.7

Authors

Rajni Dawar Department of Biochemistry, LHMC & SSK Hospital, Delhi, India.
Tabassum Yasmin Department of Biochemistry, RMCH, Ghaziabad, India.

DOI:

https://doi.org/10.22270/ijmspr.v1i3.7

Keywords:

NAFLD, C-Reactive Protein, Steatosis, Metabolic Syndrome

Abstract

Prevalence of Non Alcoholic Fatty Liver Disease is estimated to be around 9-32% in general Indian Population.It is more common in diabetic and obese Indiviuals. We conducted a case control study in RMCH ,a tertiary care hospital with 36 patients of diagnosed NAFLD and 30 age & sex matched controls.BMI was calculated for all subjects. Serum hs-C Reactive Protein levels were estimated by ELISA. It was found that BMI (29.61±4.89 ;23.66±3.4,p<0.001 ) and hs-CRP levels (8.9±.16; 2.3±1.6 ,p

<0.001)were significantly higher in cases compared to controls .As hs- CRP is an independent factor involved in CAD and metabolic Syndrome, it signifies increased risk of these in NAFLD. We also advocate its use for diagnostic workup & its further evaluation as a marker for NAFLD.>

Author Biographies

Rajni Dawar, Department of Biochemistry, LHMC & SSK Hospital, Delhi, India.

Department of Biochemistry, LHMC & SSK Hospital, Delhi, India.

Tabassum Yasmin, Department of Biochemistry, RMCH, Ghaziabad, India.

Department of Biochemistry, RMCH, Ghaziabad, India.

References

Angulo P (2002), “Non Alcoholic fatty Liver Disease”, N England Jour Medicine, Vol. 346, No. 16, pp. 1221-1229.

Adams L A and Angulo P (2006), “Treatment of non alcoholic fatty liver disease”, Postgrad Med J, Vol. 82, No. 967, pp. 315–22.

Kalra S, Vithalani M, Gulati G, et al (2013), “Study of prevalence of nonalcoholic fatty liver disease (NAFLD) in type 2 diabetes patients in India (SPRINT)”, J Assoc Physicians India, Vol. 61, No. 7, pp. 448-53.

Saverymuttu S H, Joseph A E and Maxwell J D (1986), “Ultrasound scanning in the detection of hepatic fibrosis and steatosis”, BMJ , Vol. 292, pp. 13-15.

Lizardi-Cervera J, Chavez-Tapia N C, Pérez Bautista O, Ramos M H and Uribe M (2007), “Association among Creactive protein, Fatty liver disease, and cardiovascular risk”, Dig Dis Sci., Vol. 52, No. 9, pp. 2375-2379.

Koruk M, Taysi S, Savas M C, et al. (2003), “Serum levels of acute phase proteins in patients with nonalcoholic steatohepatitis”, Turk J Gastroenterol, Vol. 14, No. 1, pp. 12-17.

Yoneda M, Mawatari H, Fujita K, et al. 2007), “Highsensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH”, J Gastroenterol., Vol. 42, No. 7, pp. 573-782.

Kerner A, Avizohar O, Sella R, et al. (2005), Association between elevated liver enzymes and C-reactive protein: possible hepatic contribution to systemic inflammation in the metabolic syndrome”, Arterioscler Thromb Vasc Biol, Vol. 25, No. 1, pp. 193-197